Endo and Impax had non-compete agreement, FTC says
A lower court mischaracterised an agreement between Endo Pharmaceuticals and Impax Laboratories to forgo competition over a painkiller as a valid patent licensing agreement, the Federal Trade Commission has argued on appeal before the US Court of Appeals for the District of Columbia Circuit.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10